我的购物车

Biotinylated Human G-CSF R / CD114 Protein, Avitag™,His Tag (MALS verified)

用户评价
货号-规格
价格
Qty.
合计0件 产品金额0
0
加入购物车

产品详情

  • 分子别名(Synonym)

    CSF3R,CD114,GCSFR

  • 表达区间及表达系统(Source)

    Biotinylated Human G-CSF R, Avitag,His Tag (GCR-H82E4) is expressed from human 293 cells (HEK293). It contains AA Glu 25 - Pro 621 (Accession # NP_000751).

    Predicted N-terminus: Glu 25

    Request for sequence
  • 蛋白结构(Molecular Characterization)

    G-CSF R Structure

    This protein carries an Avi tag (Avitag™) at the C-terminus, followed by a polyhistidine tag.

    The protein has a calculated MW of 69.2 kDa. The protein migrates as 85-100 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • 偶联(Conjugate)

    Biotin

  • 标记(Labeling)

    Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

  • 内毒素(Endotoxin)

    Less than 1.0 EU per μg by the LAL method.

  • 纯度(Purity)

    95% as determined by SDS-PAGE.

  • 制剂(Formulation)

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • 重构方法(Reconstitution)

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • 存储(Storage)

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • 质量管理控制体系(QMS)

    1. 质量管理体系(ISO, GMP)
    2. 质量优势
    3. 质控流程

产品展示

  • 电泳(SDS-PAGE)

    G-CSF R SDS-PAGE

    Biotinylated Human G-CSF R, Avitag,His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

  • SEC-MALS

    G-CSF R SEC-MALS

    The purity of Biotinylated Human G-CSF R, Avitag,His Tag (Cat. No. GCR-H82E4) is more than 85% and the molecular weight of this protein is around 148-184 kDa verified by SEC-MALS.

    Report
  • 活性(Bioactivity)-ELISA

     G-CSF R ELISA

    Immobilized Human G-CSF Protein, premium grade (Cat. No. GCF-H5214) at 2 μg/mL (100 μL/well) can bind Biotinylated Human G-CSF R, Avitag,His Tag (Cat. No. GCR-H82E4) with a linear range of 0.01-0.6 μg/mL (QC tested).

    Protocol

用户评价
发表评论

背景介绍

Granulocyte Colony Stimulating Factor Receptor (G-CSFR) is also known as Cluster of Differentiation 114 (CD114), CSF3R and GCSF, is a cell-surface receptor for the granulocyte colony-stimulating factor (G-CSF), a cytokine that plays a critical role in the regulation of the activation, proliferation, differentiation, and survival of the neutrophilic granulocyte lineage. G-CSFR belongs to a family of cytokine receptors known as the hematopoietin receptor family. This type I  membrane protein has a composite structure consisting of an immunoglobulin(Ig)-like domain, a cytokine receptor-homologous (CRH) domain and three fibronectin type I II (FNIII) domains in the extracellular region. G-CSFR is present mainly on precursor cells in the bone marrow, and, in response to stimulation by G-CSF, initiates cell proliferation and differentiation into mature neutrophilic granulocytes and macrophages. G-CSFR mediates the specific effect of GCSF through activating a variety of intracellular signaling cascades, including the Jak/Stat, PI3/Akt, Ras-Raf-MAP kinase, and Src family kinase pathways, and thus functions in defense against infection, inflammation and repair, and in the maintenance of steady state hematopoiesis. Mutations in this gene are a cause of Kostmann syndrome, also known as severe congenital neutropenia. Mutations in the intracellular part of this receptor are also associated with certain types of leukemia.

前沿进展

 
药物研发进展
  • 英文全称:

    Colony stimulating factor 3 receptor

  • 中文全称:

    巨噬细胞集落刺激因子3受体

  • 种类:

  • 上市药物数量:

    108 详情

  • 临床药物数量:

    34 详情

  • 最高研发阶段:

    批准上市

联系我们
项目合作
查看更多项目
  • 产品SKU
  • 产品详情
  • 产品展示
  • 用户评价
  • 背景介绍